

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV304413589US Express Mail Label Number December 4, 2006

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1656

HUANG ET AL.

Examiner: SWOPE, SHERIDAN

APPLICATION NO: 10/648,593

FILED: AUGUST 26, 2003

FOR: IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING

ACTIVITY OF COMPOUNDS THAT INTERACT WITH AND/OR MODULATE PROTEIN TYROSINE KINASES AND/OR PROTEIN

TYROSINE KINASE PATHWAYS IN BREAST CELLS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-5289

Date: December 4, 2006

Stephen C. D'Amico Agent for Applicants Reg. No. 46,652



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV304413589US Express Mail Label Number December 4, 2006

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1656

HUANG ET AL.

Examiner: SWOPE, SHERIDAN

APPLICATION NO: 10/648,593

FILED: AUGUST 26, 2003

FOR: IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING

ACTIVITY OF COMPOUNDS THAT INTERACT WITH AND/OR MODULATE PROTEIN TYROSINE KINASES AND/OR PROTEIN

TYROSINE KINASE PATHWAYS IN BREAST CELLS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in an Invitation to Pay Additional Fees in a corresponding PCT International application. Copies of these references and the search report are enclosed herewith.

Statement Under 37 C.F.R. § 1.704(d)

I, the undersigned attorney, hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application no more than 30 days prior to the filing of this Statement.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-5289

Date: December 4, 2006

Stephen C. D'Amico Agent for Applicants Reg. No. 46,652 FORM PTO-1449 (REV. 7-85)

EXAMINER

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

Puse seven sheets if necessary)

OEC 0 5 2006

ATTY. DOCKET NO. D0273 NP
APPLICATION NO. 10/648,593
APPLICANT
HUANG ET AL.
FILING DATE
AUGUST 26, 2003

Group 1656

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CI	ASS SUBCL	ASS	FILING DATE
	AA	2004/0106132 A1	6/3/04	Huang, et al.				
	AB	2006/0019284 A1	1/26/06	Huang, et al.				
	AC							
	AD							
	AE							
	AF							
	AG							
	AH	-						
	ΑI							7
	AJ							
	AK							
	AL							
	1		₇	EN PATENT DOCUMENTS			1	
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAI YES	NSLATION NO
	AM	WO2004/020583A2	3/11/04	PCT				
	AN	WO2006/005035A2	1/12/06	PCT				
	AO	WO03/062395A2	7/31/03	PCT				
	AP	WO00/62778	10/26/00	PCT ·				
	AQ	WO2004/085388A2	10/7/04	PCT				
		OTHER DO	CUMENTS	(Including Author, Title, Date, Per	tinent pages, Et	e.)		
	AR	······································						
	AR AS							

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

DATE CONSIDERED